Protein

Abstract

The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . A method for screening for and/or diagnosis of colorectal cancer in a human subject, which comprises the step of identifying the presence or absence of Cadherin-17, or a fragment thereof, in a biological sample obtained from said human subject, wherein the method comprises an immunoassay step utilising one or more antibodies or other affinity reagents such as Affibodies, Nanobodies or Unibodies against Cadherin-17 or a fragment or derivative thereof. 
     
     
         19 . A method for monitoring and/or assessing colorectal cancer treatment in a human subject, which comprises the step of identifying the presence or absence of Cadherin-17, or a fragment thereof, in a biological sample obtained from said human subject, wherein the method comprises an immunoassay step utilising one or more antibodies or other affinity reagents such as Affibodies Nanobodies or Unibodies against Cadherin-17 or a fragment or derivative thereof. 
     
     
         20 . A method for identifying the presence or absence of metastatic colorectal cancer cells in a biological sample obtained from a human subject, which comprises the step of identifying the presence or absence of Cadherin-17, or a fragment thereof, wherein the method comprises an immunoassay step utilising one or more antibodies or other affinity reagents such as Affibodies, Nanobodies or Unibodies against Cadherin-17 or a fragment or derivative thereof. 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . (canceled) 
     
     
         36 . (canceled) 
     
     
         37 . (canceled) 
     
     
         38 . (canceled) 
     
     
         39 . (canceled) 
     
     
         40 . (canceled) 
     
     
         41 . (canceled) 
     
     
         42 . (canceled) 
     
     
         43 . (canceled) 
     
     
         44 . (canceled) 
     
     
         45 . (canceled) 
     
     
         46 . (canceled) 
     
     
         47 . (canceled) 
     
     
         48 . (canceled) 
     
     
         49 . (canceled) 
     
     
         50 . (canceled) 
     
     
         51 . (canceled) 
     
     
         52 . (canceled) 
     
     
         53 . (canceled) 
     
     
         54 . (canceled) 
     
     
         55 . (canceled) 
     
     
         56 . (canceled) 
     
     
         57 . (canceled) 
     
     
         58 . (canceled) 
     
     
         59 . (canceled) 
     
     
         60 . (canceled) 
     
     
         61 . A method as claimed in  claim 18 , wherein the antibody is selected from the group consisting of polyclonal, monoclonal, bispecific, humanized, chimeric and single chain antibodies, Fab fragments and F(ab′) 2  fragments. 
     
     
         62 . A method as claimed in  claim 19 , wherein the antibody is selected from the group consisting of polyclonal, monoclonal, bispecific, humanized, chimeric and single chain antibodies, Fab fragments and F(ab′) 2  fragments. 
     
     
         63 . A method as claimed in  claim 20 , wherein the antibody is selected from the group consisting of polyclonal, monoclonal, bispecific, humanized, chimeric and single chain antibodies, Fab fragments and F(ab′) 2  fragments. 
     
     
         64 . A method as claimed in  claim 18 , wherein the antibody or affinity reagent is conjugated to a diagnostic moiety. 
     
     
         65 . A method as claimed in  claim 19 , wherein the antibody or affinity reagent is conjugated to a diagnostic moiety. 
     
     
         66 . A method as claimed in  claim 20 , wherein the antibody or affinity reagent is conjugated to a diagnostic moiety. 
     
     
         67 . A method as claimed in  claim 61 , wherein the antibody is conjugated to a diagnostic moiety. 
     
     
         68 . A method as claimed in  claim 62 , wherein the antibody is conjugated to a diagnostic moiety. 
     
     
         69 . A method as claimed in  claim 63 , wherein the antibody is conjugated to a diagnostic moiety.